Susquehanna International Group
ZNTL icon

Susquehanna International Group’s Zentalis Pharmaceuticals ZNTL Stock Holding History

Susquehanna International Group’s Portfolio ZNTL Stock Details ZNTL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$1.34M Buy
571,257
+560,914
+5,423% +$1.45M ﹤0.01% 7172
2025
Q4 		$14K Sell
10,343
-190,766
-95% -$278K ﹤0.01% 12016
2025
Q3 		$304K Buy
201,109
+55,340
+38% +$83K ﹤0.01% 10080
2025
Q2 		$169K Buy
145,769
+40,082
+38% +$52.9K ﹤0.01% 11377
2025
Q1 		$168K Buy
105,687
+61,707
+140% +$133K ﹤0.01% 11114
2024
Q4 		$133K Sell
43,980
-77,115
-64% -$253K ﹤0.01% 11109
2024
Q3 		$446K Buy
121,095
+77,018
+175% +$280K ﹤0.01% 8747
2024
Q2 		$180K Buy
44,077
+17,050
+63% +$190K ﹤0.01% 10507
2024
Q1 		$426K Sell
27,027
-8,565
-24% -$118K ﹤0.01% 8897
2023
Q4 		$539K Buy
35,592
+11,254
+46% +$164K ﹤0.01% 8476
2023
Q3 		$488K Buy
24,338
+9,584
+65% +$243K ﹤0.01% 8279
2023
Q2 		$416K Sell
14,754
-64,533
-81% -$1.55M ﹤0.01% 8744
2023
Q1 		$1.36M Buy
79,287
+57,080
+257% +$1.16M ﹤0.01% 6034
2022
Q4 		$447K Sell
22,207
-52,814
-70% -$1.14M ﹤0.01% 8161
2022
Q3 		$1.63M Buy
75,021
+66,153
+746% +$1.81M ﹤0.01% 5403
2022
Q2 		$249K Sell
8,868
-21,298
-71% -$564K ﹤0.01% 10079
2022
Q1 		$1.39M Sell
30,166
-1,727
-5% -$93.2K ﹤0.01% 6326
2021
Q4 		$2.68M Sell
31,893
-16,458
-34% -$1.27M ﹤0.01% 4849
2021
Q3 		$3.22M Buy
48,351
+30,978
+178% +$1.79M ﹤0.01% 4807
2021
Q2 		$924K Buy
17,373
+10,863
+167% +$582K ﹤0.01% 7986
2021
Q1 		$282K Buy
6,510
+118
+2% +$5.08K ﹤0.01% 10748
2020
Q4 		$332K Buy
+6,392
New +$288K ﹤0.01% 9075

Other funds holding ZNTL

5VM
5AM Venture Management San Francisco, California $360M AUM 345.76% 1-Year Est. Return
SCM
Squadron Capital Management Westmont, Illinois $273M AUM
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
OM
Opaleye Management Boston, Massachusetts $759M AUM 124.8% 1-Year Est. Return
DC
Decheng Capital Menlo Park, California $661M AUM 299.97% 1-Year Est. Return

Susquehanna International Group's ZNTL Position: Q1 2026 in Review

Susquehanna International Group increased its Zentalis Pharmaceuticals (ZNTL) stake by 5,423% in Q1 2026, buying an estimated $1.45M and bringing the position to 571,257 shares worth $1.34M. The position accounts for ﹤0.01% of the portfolio, ranked #7172.

Susquehanna International Group first reported a position in ZNTL in Q4 2020 and has held it in 22 quarters since. The position peaked at $3.22M in Q3 2021. 102 funds tracked by Wall St. Rank hold ZNTL as of Q1 2026.

  • Susquehanna International Group held 571,257 shares of Zentalis Pharmaceuticals worth $1.34M as of Q1 2026.
  • Susquehanna International Group bought 560,914 Zentalis Pharmaceuticals shares in Q1 2026, an estimated $1.45M.
  • Zentalis Pharmaceuticals made up ﹤0.01% of Susquehanna International Group's portfolio in Q1 2026, its #7172 holding.
  • Susquehanna International Group first reported a position in Zentalis Pharmaceuticals in Q4 2020 and has held it in 22 quarters since.
  • Susquehanna International Group's Zentalis Pharmaceuticals position peaked at $3.22M in Q3 2021.
  • 102 funds tracked by Wall St. Rank held Zentalis Pharmaceuticals as of Q1 2026.

Based on Susquehanna International Group's 13F filing for Q1 2026, filed 15 May 2026.